, Tracking Stock Market Picks
Enter Symbol:
Inovio Biomedical Corporation (INO) [hlAlert]

down 46.22 %

Inovio Biomedical Corporation (INO) upgraded to Buy with price target $19 by Aegis Capital

Posted on: Thursday,  Jul 24, 2014  12:00 AM ET by Aegis Capital

Aegis Capital rated Buy Inovio Biomedical Corporation (NASDAQ: INO) on 07/24/2014, when the stock price was $12.98. Since
then, Inovio Biomedical Corporation has lost 46.22% as of 01/05/2016's recent price of $6.98.
If you would have followed this Aegis Capital's recommendation on INO, you would have lost 46.22% of your investment in 530 days.

Inovio Biomedical Corporation (Inovio) is a San Diego-based biomedical company focused on the development of vaccines to prevent or treat cancers and chronic infectious diseases. Inovio develops deoxyribonucleic acid (DNA) delivery solutions based on electroporation, which uses brief, controlled electrical pulses to create temporary pores in cell membranes and enable increased cellular uptake of a useful biopharmaceutical. Once the DNA vaccine enters a cell, it can then express the proteins it was encoded to produce. Inovio has multiple systems designed to create different electroporation conditions for different applications consists of two documents: a pulse generator and an applicator that is inserted into selected tissue. The Company?s subsidiaries include Genetronics, Inc., Inovio AS and Inovio Asia Pte. Ltd. In June 2009, Inovio completed its merger with VGX Pharmaceuticals.

Aegis Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/24/2014 12:00 AM Buy
12.98 19.00
as of 10/17/2014
1 Week up  22.60 %
1 Month up  18.25 %
3 Months down  -5.16 %
1 YTD down  -5.16 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/16/2013 8:25 AM Hold
3/11/2013 10:25 AM Buy
2.12 6.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy